No title
BACKGROUND: CFTR modulators, including Elexacaftor/Tezacaftor/Ivacaftor (ETI), have markedly improved clinical outcomes for people with cystic fibrosis (pwCF), but the molecular impact on airway inflammation remains incompletely understood. This study aimed to characterise longitudinal changes in airway inflammation and sputum proteomes following ETI treatment.METHODS: Sputum from pwCF (n = 30) wa
